接受新辅助全身治疗的早期乳腺癌的诊断与治疗
Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy.
作者信息
Belli Paolo, Palma Simone, Costantini Melania
机构信息
Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy.
出版信息
Cancers (Basel). 2023 Oct 7;15(19):4874. doi: 10.3390/cancers15194874.
Abstract
Breast cancer (BC) remains a major challenge for oncology today, impacting the lives of countless individuals worldwide [...].
摘要
乳腺癌（BC）如今仍是肿瘤学面临的一项重大挑战，影响着全球无数人的生活。
相似文献
1
Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy.接受新辅助全身治疗的早期乳腺癌的诊断与治疗
Cancers (Basel). 2023 Oct 7;15(19):4874. doi: 10.3390/cancers15194874.
2
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.接受新辅助治疗的II-III期乳腺癌女性患者的卵巢刺激生育力保存及治疗时机
Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13.
3
Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.局部晚期乳腺癌新辅助化疗应用的差异：荷兰国家乳腺癌审计结果。
Breast. 2017 Dec;36:34-38. doi: 10.1016/j.breast.2017.08.011. Epub 2017 Sep 20.
4
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
5
[Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].[HER2/neu基因簇扩增作为II-III期乳腺癌患者对曲妥珠单抗新辅助抗HER2治疗特殊敏感性标志物的作用]
Arkh Patol. 2019;81(6):56-62. doi: 10.17116/patol20198106156.
6
Deep learning radiomics of ultrasonography can predict response to neoadjuvant chemotherapy in breast cancer at an early stage of treatment: a prospective study.深度学习超声放射组学可预测早期治疗阶段乳腺癌新辅助化疗的反应：一项前瞻性研究。
Eur Radiol. 2022 Mar;32(3):2099-2109. doi: 10.1007/s00330-021-08293-y. Epub 2021 Oct 15.
7
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.新辅助化疗延迟对乳腺癌患者总生存的影响。
Oncologist. 2020 Sep;25(9):749-757. doi: 10.1634/theoncologist.2019-0744. Epub 2020 Jul 7.
8
Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.早期乳腺癌的新辅助治疗：当前实践、争议及未来方向
Oncology (Williston Park). 2015 Nov;29(11):828-38.
9
Complete Metabolic Response on Interim F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.基于中期氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的完全代谢反应预测接受新辅助化疗的乳腺癌患者的长期生存情况
Oncologist. 2017 May;22(5):526-534. doi: 10.1634/theoncologist.2016-0334. Epub 2017 Apr 4.
10
The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data.添加新辅助帕妥珠单抗治疗HER2阳性乳腺癌：基于真实世界数据的成本估算
Health Econ Rev. 2021 Sep 10;11(1):33. doi: 10.1186/s13561-021-00332-0.
本文引用的文献
1
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.早期HER2阳性乳腺癌全身治疗策略评估——文献综述
Cancers (Basel). 2023 Aug 30;15(17):4336. doi: 10.3390/cancers15174336.
2
Image-Guided Localization Techniques for Metastatic Axillary Lymph Nodes in Breast Cancer; What Radiologists Should Know.乳腺癌腋窝转移性淋巴结的图像引导定位技术；放射科医生应了解的内容。
Cancers (Basel). 2023 Apr 3;15(7):2130. doi: 10.3390/cancers15072130.
3
Selective Axillary Dissection after Neoadjuvant Chemotherapy in Patients with Lymph-Node-Positive Breast Cancer (CLYP Study): The Radio-Guided Occult Lesion Localization Technique for Biopsy-Proven Metastatic Lymph Nodes.淋巴结阳性乳腺癌患者新辅助化疗后选择性腋窝清扫术（CLYP研究）：针对活检证实的转移性淋巴结的放射性引导隐匿病变定位技术
Cancers (Basel). 2023 Mar 29;15(7):2046. doi: 10.3390/cancers15072046.
4
Surgical Planning after Neoadjuvant Treatment in Breast Cancer: A Multimodality Imaging-Based Approach Focused on MRI.乳腺癌新辅助治疗后的手术规划：一种基于多模态成像且聚焦于MRI的方法
Cancers (Basel). 2023 Feb 24;15(5):1439. doi: 10.3390/cancers15051439.
5
Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI.使用纵向动态对比增强MRI的功能性肿瘤体积评估三阴性乳腺癌对新辅助全身治疗的反应
Cancers (Basel). 2023 Feb 6;15(4):1025. doi: 10.3390/cancers15041025.
6
Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting.利用磁共振成像对乳腺癌进行分期，T. 在新辅助治疗环境中发挥关键作用。
Cancers (Basel). 2022 Nov 24;14(23):5786. doi: 10.3390/cancers14235786.
7
Beyond N Staging in Breast Cancer: Importance of MRI and Ultrasound-based Imaging.乳腺癌N分期之外：基于MRI和超声成像的重要性
Cancers (Basel). 2022 Aug 31;14(17):4270. doi: 10.3390/cancers14174270.
8
Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.早期三阴性乳腺癌新辅助治疗的最新进展：免疫疗法、潜在预测生物标志物及新型药物
Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
9
Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy.接受新辅助化疗的女性五年乳腺癌复发的多模态预测
Cancers (Basel). 2022 Aug 9;14(16):3848. doi: 10.3390/cancers14163848.
10
Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3, CD8, and Immunoscore Are Associated with a Pathological Complete Response.早期乳腺癌患者的肿瘤浸润淋巴细胞（TILs）：高CD3、CD8及免疫评分与病理完全缓解相关。
Cancers (Basel). 2022 May 20;14(10):2525. doi: 10.3390/cancers14102525.
Zotero 插件